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Abstract
Background: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of
tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for
prognosis and prediction. However, the comprehensive analysis of tyrosine phosphorylation of large numbers of human
cancer specimens is technically challenging using current methods.
Methodology/Principal Findings: We used a phosphoproteomic method termed SH2 profiling to characterize the global
state of phosphotyrosine (pTyr) signaling in human lung cancer cell lines. This method quantifies the phosphorylated binding
sitesforSH2domains,whichareusedbycellstorespondtochangesinpTyrduringsignaling.Cellscouldbegroupedbasedon
SH2bindingpatterns,withsomeclusterscorrelatedwith EGFreceptor(EGFR)orK-RASmutation status.BindingofspecificSH2
domains, most prominently RAS pathway activators Grb2 and ShcA, correlated with EGFR mutation and sensitivityto the EGFR
inhibitor erlotinib. SH2 binding patterns also reflected MET activation and could identify cells driven by multiple kinases. The
pTyr responses of cells treated with kinase inhibitors provided evidence of distinct mechanisms of inhibition.
Conclusions/Significance: This study illustrates the potential of modular protein domains and their proteomic binding
profiles as powerful molecular diagnostic tools for tumor classification and biomarker identification.
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Introduction
Receptor and non-receptor tyrosine kinases regulate many
activities important for cancer, including cell proliferation,
survival, invasion/metastasis, and angiogenesis [1]. These signal-
ing proteins therefore represent an important class of drug targets
for the treatment of cancer, and numerous tyrosine kinase
inhibitors (TKIs) are under development or are now being used
in the clinic. Lung cancer accounts for over 160,000 deaths per
year in the U.S. [2], so there is a powerful rationale to identify key
drivers of lung cancer that can be therapeutically exploited. The
activity of the epidermal growth factor receptor (EGFR) is
frequently elevated in lung cancer, and inhibition of EGFR
through the TKI erlotinib can extend survival in patients with
advanced lung cancer refractory to chemotherapy [3]. In addition
to EGFR, a number of other tyrosine kinases have been proposed
as therapeutic targets in lung cancer, including MET, insulin-like
growth factor receptors (IGFR), SRC kinases, fibroblast growth
factor receptors (FGFR), platelet-derived growth factor receptors
(PDGFR), anaplastic lymphoma kinase (ALK), and EPH receptors
[4,5,6,7,8,9,10,11,12].
A key question in TKI therapy for lung cancer is which patients
will benefit from these drugs, since the cost is substantial and many
receive no benefit from treatment. An important breakthrough
was the discovery of activating somatic mutations in EGFR that
enhance receptor signaling and predict sensitivity to TKIs
targeting the EGFR, such as erlotinib and gefitinib [13,14,15].
In lung cancer patients harboring these mutations, response rates
to EGFR TKIs can be high and survival is better than that seen
with cytotoxic agents [16]. Nonetheless some patients without
EGFR mutation can benefit from EGFR inhibitors, and markers
such as EGFR gene amplification, autocrine TGFa production, or
gene expression profiles have been proposed to identify these
patients [17,18,19]. In addition, resistance mechanisms such as
MET amplification or secondary mutations in EGFR can rapidly
lead to drug resistance [20,21,22]. Finally, some tumor cells are
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identify and classify these are needed [23].
Proteomic strategies (which examine global patterns of protein
expression or phosphorylation) are also being used to classify tumors
[24]. Mass spectrometry (MS) coupled with anti-phosphotyrosine
antibodies identified different patterns of tyrosine kinase signaling in
lung cancer cells and tumors, and this approach was able to identify
cells driven by oncogenic EGFR, PDGFR, and ALK [4]. Other
studies using the same approach found patterns of tyrosine
phosphorylation associated with mutant EGFR signaling [25,26].
Overall, this work provides proof of principle that global tyrosine
phosphorylation patterns can provide useful information for tumor
classification.However,currentMSmethodsrequire relativelylarge
amounts of sample and quantification of phosphorylated sites is
challenging, thus new phosphoproteomic strategies are needed.
We have developed an alternative phosphoproteomic method,
termed SH2 profiling, that complements MS-based approaches
[27,28]. SH2 profiling is highly sensitive and throughput is
relatively high, thus it is ideal for profiling phosphotyrosine (pTyr)
signaling in cancer cells. The conceptual basis of SH2 profiling is
to use the cell’s own pTyr signal response apparatus to interrogate
the state of pTyr signaling. Upon receptor tyrosine kinase (RTK)
activation, the resulting increase in protein tyrosine phosphoryla-
tion generates binding sites for modular pTyr-specific binding
domains; it is the relocalization of intracellular effectors containing
pTyr binding domains to these phosphorylated sites that is the key
step in signal transmission [29]. By far the most abundant pTyr
binding module in humans is the Src Homology 2 or SH2 domain
[30]. There are 120 SH2 domains encoded by the human genome,
and each SH2 domain binds a unique spectrum of tyrosine
phosphorylated sites [28,31]. Because SH2 domains are what the
cell uses to respond to or ‘‘read’’ changes in tyrosine phosphor-
ylation during signaling, the extent of binding of different SH2
domains can provide a wealth of information about the
mechanisms and status of pTyr signaling.
To test if this approach is useful in characterizing and classifying
complex tumor types such as lung cancer, where multiple tyrosine
kinases drive downstream signaling and maintain tumor growth,
we applied SH2 profiling to lung cancer cell lines. We find that
pTyr patterns could be related to known features of the cells
including EGFR mutation status and sensitivity to EGFR TKI.
Our results suggest that SH2 profiling provides novel insights into
pTyr signaling that are likely to be useful for prediction and
prognosis of lung cancer.
Results
SH2 profiling identifies subsets of lung cancer cell lines
We selected a group of 22 non-small cell lung cancer cell lines
with known EGFR and K-RAS mutation status and known
sensitivity to the EGFR TKI erlotinib (Suppl. Table S1). The
overall strategy for our studies is shown in Fig. 1. Cell lysates were
prepared from actively growing cells cultured in serum-supple-
mented medium. Two approaches to generate SH2 profiles were
used, reverse-phase protein array and far-Western blotting [28]. In
the first method, multiple protein samples (cell lysates) are spotted
in arrays in register with the wells of a 96-well chamber apparatus.
Each well is then filled with a solution containing a different GST-
SH2 domain probe, and after incubation and washing, the bound
probe is quantified for each spot. The amount of binding depends
on the number and affinity of tyrosine phosphorylated protein sites
in the sample. With this approach, which we term the ‘‘rosette’’
assay, it is possible to profile the total level of binding for virtually
all SH2 domains in the genome (94 SH2 domain probes and one
PTB domain representing 90 distinct proteins) using minimal
amounts of protein sample.
To investigate the relatedness of different cell lung cancer cell
lines, quantitative SH2 binding values were subjected to
unsupervised hierarchical clustering analysis (see Methods).
Results are shown in heat map format in Fig. 2A and the raw
image data is shown in Suppl. Fig. S1. Data with low signal/
background were discarded; data for the remaining 70 probes
were median-centered for clustering; red indicates higher than
median binding, green lower. The processed data can be found in
Suppl. Table S2. Data can also be accessed using a web-based
viewer (http://proteome.moffitt.org/sh2/). In this analysis, cell
lines harboring mutant EGFR cluster together in three distinct
sub-clusters, while two large clusters (of four and eight cell lines)
consist entirely of lines with wild-type (wt) EGFR. These results
suggest that SH2 profiling can identify subsets of lung cancer cells,
and that such clusters appear related to EGFR mutation status.
The second SH2 profiling approach uses far-Western blotting to
obtain more detailed information about the relative abundance
and apparent molecular weight (MW) of phosphoproteins that
bind different SH2 domain probes. Protein samples are separated
on the basis of size by gel electrophoresis and transferred to
membranes, which are then probed with labeled SH2 domains.
SH2 binding proteins are revealed as bands, and the apparent
MW of these bands may provide clues to their identity. We
developed software tools that allow SH2 binding data from far-
Western blots to be quantified in ‘‘bins’’ by apparent MW, e.g. 20
bins per lane. The data from each bin (corresponding to
phosphoproteins of a particular MW range that bind to the SH2
probe) can then be used as the basis for classification of samples.
Thus instead of a single value for each sample and SH2 domain, as
in the rosette assay, quantitative far-Western blotting provides at
least 20 different data points, greatly increasing the potential
discrimination between samples.
Far-Western blots of lung cancer cell lines were probed with 36
SH2 or PTB domains, as well as anti-pTyr antibody. Raw image
data can be found in Suppl. Movie S1, and quantitative data in
Suppl. Table S2. When quantitative results were subjected to
hierarchical clustering, the samples clustered into 3 distinct classes,
plus two outliers (Fig. 2B). One of these (cluster 3) consists entirely
of cells with wt EGFR and is highly enriched for cells with
activating K-RAS mutations. In contrast, clusters 1 and 2 are
enriched for cells with EGFR mutations; within each of these
clusters, cells with wt and mutant EGFR are segregated. Thus
quantitative far-Western blotting appears to provide additional
information on tyrosine kinase signaling state that can be used to
functionally classify cells on the basis of RTK activation status.
Overall the clustering results from the Rosette and far-Western
assays are similar but not identical, as discussed below.
Binding of a set of SH2 domains is enhanced in cells
harboring activating EGFR mutations
We next asked whether the binding of any individual SH2
domain probes was highly associated with activating EGFR
mutations. From rosette binding experiments we identified 7
probes whose binding was correlated in a statistically significant
fashion with EGFR mutation status: Grb2, ShcA(ptb), Grap2, Brk,
Txk, CblB and CblA (Fig. 3A) (refer to Suppl. Table S3 for SH2
domain names and corresponding proteins). We input these
domains into PPI Spider, a tool for interpreting proteomics data in
the context of known protein-protein interaction networks. This
analysis showed that five of these proteins (ShcA, Grb2, CblA,
CblB, and Brk) have been reported to bind directly to EGFR,
while Grap2 is potentially linked to EGFR through ShcA (Fig. 3B).
SH2 Profiling of Lung Cancer
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relative Grap2) are closely associated with EGFR mutation is
particularly intriguing, as increased binding of these SH2 domains
would be strongly predicted to lead to activation of the RAS
signaling pathway via recruitment of the RAS activator Sos
[32,33].
A similar analysis was performed using data from far-Western
blotting. We found that a number of specific bands on far-Western
blots correlated significantly with EGFR mutation (Fig. 3C). Here
it is interesting to consider bands whose binding tends to increase
in EGFR mutant cells (red) versus those whose binding tends to
decrease in EGFR mutant cells (green). We note that for probes
predicted (on the basis of known signaling activity) to be associated
with stimulation of the RAS pathway (Grb2 and Shc), increased
binding in the molecular weight range containing phosphorylated
EGFR family members (MW194, arrow) is seen for EGFR mutant
cells. This likely reflects increased binding of these effectors to
abnormally activated EGFR, compared with the wt receptor. This
is also true for SH2 domains of other known positive effectors of
EGFR signaling, including Vav2, PI 3-kinase (PI3K; P85B), and
PLCc Plcg1).
In contrast to EGFR mutation, we found no individual SH2
domains whose binding correlated strongly with RAS mutation
status by rosette or far-Western blotting. Despite this, we noticed
an interesting apparent correlation between clustering based on
global SH2 profiles and K-RAS mutation status. This is
particularly clear in the case of far-Western blotting (Fig. 2B),
where two major clusters consist entirely of cells with wt K-RAS,
whereas a third major cluster (cluster 3) consists almost entirely of
cells with wt EGFR but mutant K-RAS. We were initially puzzled
by the appearance of H1299 in cluster #3, as K-RAS is wt in these
cells. However, further examination of sequence data revealed that
the K-RAS relative N-RAS is mutated in H1299 (http://www.
sanger.ac.uk/genetics/CGP/CellLines/), but not in any of the
other cell lines used in this study. Thus a prediction based on SH2
profiling, that H1299 cells are likely to harbor activated RAS, was
borne out, strongly validating the biological relevance of this
approach. This cluster of RAS mutants (6 of 6 cell lines harboring
RAS mutation) is highly unlikely to have occurred by chance
(p=0.001, permutation test, n=100,000). These results indicate
that tyrosine phosphorylation patterns can sub-classify cells based
on RAS mutation status. The lack of correlation between
individual SH2 domain probes and RAS mutation (as opposed
to correlation based on the global tyrosine phosphorylation profile)
may reflect the fact that RAS functions downstream of tyrosine
kinases. We are currently testing the model that constitutive Ras
activity leads to activation of feedback pathways that broadly
downregulate tyrosine kinase signaling.
Figure 1. Overview of approach. Human lung cancer cell lines (Suppl. Table S1) were cultured in the presence or absence of tyrosine kinase
inhibitors erlotinib or dasatinib. Cell proteins were extracted and analyzed by rosette and far-Western blotting using an array of SH2 domain probes
(Suppl. Table S3). Bioinformatic analysis of quantified data was used for classification and biomarker screening.
doi:10.1371/journal.pone.0013470.g001
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PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13470Figure 2. Unsupervised clustering of lung cancer cell lines based on SH2 binding. (A) Rosette data clustered by SH2 domain and cell line.
Each row represents a single SH2 domain and each column represents a single cell line. Biological characteristics (EGFR mutation, K-RAS mutation,
erlotinib sensitivity) are shown above in black and white. For erlotinib sensitivity, positive/sensitive: IC50 ,10 nM; intermediate/moderately sensitive:
10–1000 nM; negative/insensitive: .1000 nM. (B) Far-Western data clustered by SH2 domain-specific bin and cell line. Each row represents a single
MW bin (20 bins/lane) for a particular SH2 domain and each column represents a single cell line.
doi:10.1371/journal.pone.0013470.g002
SH2 Profiling of Lung Cancer
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13470Figure 3. SH2 domains correlated with EGFR mutation. (A) SH2 domains whose binding is significantly correlated with EGFR mutation
(q,0.1). Bar plot of SH2 signal for mutant and wild-type EGFR cell lines is shown as mean with standard error bars. "SH2 domain" is used in figures for
all probes, including PTB domains and anti-pTyr antibody. (B) Protein-protein interaction map for EGFR (gray circle) and proteins with SH2 domains
whose binding is significantly correlated with EGFR mutation (white circles). Lines indicate reported direct binding interactions. (C) Far-Western
domain-specific bands significantly correlated with EGFR mutation. Colored boxes indicate the results of statistical significance in a Mann-Whitney
SH2 Profiling of Lung Cancer
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cancer cells to EGFR TKI
We next determined if SH2 domain binding correlated with the
sensitivity of lung cancer cell lines to erlotinib, a small molecule
EGFR kinase inhibitor. Such domains could serve as the basis for
predictive biomarkers to identify tumors likely to respond to TKI
therapy. SH2 profiling data were examined for possible correlation
with the IC50 for erlotinib for each cell line (IC50 was assayed for
this study under the same culture conditions used for SH2
profiling). We found that the binding of 13 probes corresponding
to 12 proteins correlated in a statistically significant fashion with
erlotinib IC50 (Fig. 4A). These include Grb2 (shown in Fig. 4B),
ShcA, ShcA (ptb), p85B, Cis1, Arg, Eat2, Plcg1, Ptk70/Srms, Fes,
Lnk, Tem6, and Btk. Network analysis confirms reports of direct
test for differences (q,0.1) among the 22 cell lines shown in Figure 2B. Arrow indicates bin corresponding to EGFR family members. The numbers
adjacent to bins indicate apparent MW, e.g. "291.0" = MW between 256–291 kDa.
doi:10.1371/journal.pone.0013470.g003
Figure 4. Correlation of SH2 binding with erlotinib sensitivity. SH2 domain signal in untreated cells was compared to ln IC50 for erlotinib.
(A) Domains significantly correlated to ln IC50. Negative correlations indicate higher SH2 binding in cells more sensitive (lower IC50) to erlotinib.
(B) Scatter plot of Grb2 SH2 domain binding vs. the ln (IC50) for erlotinib. (C) Protein-protein interaction map for EGFR and proteins with SH2 domains
whose binding is significantly correlated with erlotinib sensitivity. Lines indicate reported direct binding interactions. (D) Heatmap representing
correlation of each domain-specific bin to erlotinib sensitivity. Pearson’s correlation was calculated for each domain-specific bin across 22 cell lines
and the ln (IC50) for the corresponding cell line. Each heatmap location represents correlation coefficient for that bin; green indicates increasing SH2
signal with decreasing IC50 values (greater sensitivity); red indicates increasing SH2 signal with increasing IC50 values (see color bar). Arrow indicates
MW bin containing EGFR family proteins. (E) List of the 46 domain-specific bins with |correlation coefficient| .0.5.
doi:10.1371/journal.pone.0013470.g004
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Plcg1, Fes, and Btk (Fig. 4C). Overall the results are consistent
with a model where erlotinib sensitivity is associated with
particularly strong signaling from activated EGFR to known core
downstream effectors, including the MAPK (Grb2 and ShcA),
PI3K/Akt (p85B), and PLCc (PLCg1) pathways.
Far-Western blotting also identified bands that correlated with
erlotinib sensitivity (Fig. 4D&E). For a large number of SH2
domains, higher apparent binding to EGFR family members
(arrow at MW194 in Fig. 4D) was associated with erlotinib
sensitivity, while CSK (which downregulates Src-family kinases)
was unique in that lower apparent binding of its SH2 domain to
EGFR was associated with erlotinib sensitivity. These results were
very similar to those seen for EGFR mutation (Fig. 3C), suggesting
that increased binding of RAS activators and decreased binding of
CSK to EGFR are associated both with EGFR mutation and
erlotinib sensitivity. While in principle our analysis could be
confounded by the known correlation between EGFR mutation
and erlotinib sensitivity, we included in our analysis several lines
that are resistant to erlotinib despite having activating EGFR
mutations (H1975, H820, H2279, and H1650), as well as lines
with wt EGFR that are sensitive to erlotinib (H292, H358, H1648,
and H322). It is particularly intriguing that CSK is the only SH2
domain whose binding to the region of the blot containing EGFR
decreases in both EGFR mutant cells and in cells sensitive to
erlotinib. CSK negatively regulates Src family kinases, a key class
of nonreceptor tyrosine kinases [34]. Although CSK SH2 binding
is relatively weak and differences between the cell lines are modest,
we have confirmed the statistical significance of the correlation in
several separate experiments (Suppl. Fig. S2).
MET activation is captured by SH2 profiling
A potential strength of SH2 profiling would be to identify
tumors in which multiple hyperactivated tyrosine kinases act in
concert to drive downstream signaling, so we investigated whether
SH2 profiling could identify cell lines in which MET and EGFR
are co-activated. The MET kinase is amplified in H820 and
H1648 cells [20,35], which cluster closely together by both Rosette
and far-western SH2 profiling (Fig. 2). In far-Western blots, we
also noted strong binding of multiple SH2 domains including p85a
to the region of ,148 kDa in H820 and H1648. We observed a
similar band at ,148 kDa for a number of other cell lines,
including HCC827, H4006, H358, and H441 (Fig. 5A). Suspect-
ing this band was a marker for MET activation, we tested this by
probing immunoblots with a phosphospecific antibody that
specifically recognizes activated MET (Suppl. Fig. S3A). This
analysis, together with immunoprecipitation and inhibitor studies,
demonstrated that phosphorylation of the 148 kDa band was
strongly dependent on MET activation (its presence correlated
with activated MET and was inhibited by MET-specific TKI), but
the band was not the MET receptor itself (Suppl. Fig. S3B,C). At
the same time, we indirectly examined the activity of EGFR family
members by quantifying tyrosine phosphorylation of the
,194 kDa region of immunoblots, where EGFR family members
are found (Suppl. Fig. S3A). Immunoprecipitation and inhibitor
studies showed that most of the SH2 binding signal in this region
of the blots could be attributed to EGFR family members (Suppl.
Fig. S3B,C).
We then related MET and EGFR activation state with SH2
profiling results. Remarkably, unsupervised clustering of both
rosette and far-Western data revealed that most cell lines with
strong MET activation cluster in a distinct, tight group
(Fig. 5B&C). Both by rosette and far-Western-based profiling,
most cell lines with strong MET activation form a single cluster
(cluster 1) that is clearly separated from the other cell lines. All of
these cell lines also exhibit strong tyrosine phosphorylation of
proteins co-migrating with EGFR, suggesting co-activation of
MET and EGFR signaling in this group. Information on MET
and EGFR activation also allowed us to more broadly compare
clustering results based on rosette and far-Western data. This
comparison revealed that four distinct clusters were common to
both methods (Fig. 5B,C), encompassing 15 out of the 22 cell lines
(7 lines cluster differently when the two methods are compared).
Cluster 1 consists of cell lines with strong activation of both EGFR
and MET signaling. Cluster 3 consists of cell lines with mutant
RAS and low EGFR and MET activity, all of which are erlotinib
resistant. Cluster 2 can be divided into two subgroups based on
EGFR mutation status. From a clinical perspective these two
subgroups are the most interesting: one consists of lines with
mutant EGFR that are erlotinib resistant (cluster 2b), and the
other includes several lines with wt EGFR that are erlotinib
sensitive.
Next we tested whether the binding of any individual SH2
domain probes was associated with MET activation. By rosette
analysis we found that the binding of 46 SH2 domains was
significantly associated with MET phosphorylation (Fig. 6A).
Similarly, far-Western analysis showed a large number of bands
associated with MET phosphorylation status (Fig. 6B). The
number of SH2 domains and markers that correlate with MET
activation is larger than those associated with EGFR mutation,
suggesting MET activity has a more profound effect on overall
pTyr patterns than EGFR mutation.
The fact that the H1648 cell line clustered tightly with the H820
cell line, which had previously been found to have an activating
EGFR mutation along with MET amplification [20], suggested
that H1648 cells may be similar to H820 in that downstream
signaling is driven by both EGFR and MET. To test this, we
exposed H1648 cells to inhibitors of EGFR (erlotinib), MET
(PHA665752) [36], or the combination and examined downstream
Akt and ERK activation (Fig. 6C). We observed modest reductions
in phosphorylated Akt and ERK in response to either inhibitor
alone, but strong inhibition upon dual EGFR and MET
inhibition. The effects on cell viability mirrored the signaling
responses, as the combination of both agents resulted in enhanced
inhibition of cell growth (Fig. 6D). Thus global pTyr patterns,
assayed by SH2 profiling, predict MET activation and may predict
response to MET TKI in these cell lines.
Perturbation of global pTyr profiles by TKIs
We next used SH2 domain profiling to investigate changes in
global tyrosine phosphorylation in cells exposed to TKIs. Our
expectation was that changes in SH2 binding patterns could be
correlated with biological responses to inhibitors, and that probes
for which binding decreased strongly in TKI-inhibited cells were
likely to represent key pathways for TKI action. Four lung cancer
cell lines (H292, H441, H358 and HCC827) were briefly exposed
to erlotinib, an inhibitor of EGFR, or dasatinib, a SRC family
kinase inhibitor that inhibits multiple tyrosine and serine/
threonine kinases [37,38,39]. These cell lines differ greatly in
their responses to these TKI. In HCC827 cells with activating
EGFR mutation, both inhibitors induce apoptosis; in H358 and
H292 cells with wt EGFR, both agents induce cell cycle arrest; and
H441 cells with wt EGFR are resistant to both agents ([9] and data
not shown). Rosette and far-western SH2 profiling was performed
for all four cell lines in both the treated and untreated groups.
Rosette binding data (log2 fold changes in treated versus
untreated groups) were visualized in waterfall plots ranking
changes in SH2 binding (Fig. 7A, Suppl. Fig. S4A). In HCC827,
SH2 Profiling of Lung Cancer
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decreases in SH2 binding are observed for almost all probes. The
most significant reductions in binding occurred for the Grb2,
Grap2, Vav2, and Vav1 SH2 domains. Broadly similar changes
were observed upon dasatinib treatment, suggesting an overlap of
mechanism, yet fold changes were less for most probes, consistent
with its less potent effects on EGFR phosphorylation [9]. Similar
to HCC827, binding of almost all SH2 domain probes was
markedly reduced in TKI-treated H358 cells, and there was even
greater similarity between the responses to erlotinib and dasatinib.
Figure 5. SH2 profiling identifies cells with EGFR and MET co-activation. (A) Far-Western blot of lung cancer cell lines probed with p85A
SH2 domains. Note prominent band of ,145 kDa in H820 (arrow). (B,C) Hierarchical clustering related to MET and EGFR family activation. Hierarchical
clustering based on rosette data (B) or far-Western data (C), as previously shown in Fig. 2. Colors indicate cell lines that co-cluster by both rosette and
far-Western analysis (clusters 1, 2, 2b, and 3). MET activation = immunoreactivity with phosphospecific MET antibody. pTyr MW 194=
immunoreactivity with anti-pTyr in 194 kDa bin, which is a readout of EGFR family activation (see Suppl. Fig. S3). Cutoffs for MET activation: positive,
.50% highest value in immunoblotting with anti-MET pY1334/1335; intermediate, 25–50%; negative, ,25%. Cutoff for pTyr MW194: positive, .25%
highest value in immunoblotting with anti-pTyr; intermediate, 10–25%; negative, ,10%.
doi:10.1371/journal.pone.0013470.g005
SH2 Profiling of Lung Cancer
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PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13470In H441, which is resistant to TKI, erlotinib and dasatinib evoke
similar overall patterns of change as H358. However the decrease
in SH2 binding was blunted in H441 compared to H358 and
HCC827, and the binding of a larger number of SH2 domains
increased in the presence of both inhibitors compared to untreated
cells. Finally, H292 showed the least dramatic changes in SH2
domain binding, and the overall pattern of response to TKI
treatment in this cell line was very different from the other three.
Furthermore, the erlotinib and dasatinib profiles were more
dissimilar compared to the other cell lines tested. The same
samples were also analyzed by far-Western blotting using a limited
set of SH2 probes (Suppl. Fig. S4B). These data showed that
responses to erlotinib and dasatinib were quite similar in the H358
and H441 cells, again arguing that the two agents have similar
targets in these cells.
In an effort to understand the biological implications of these
results, we compared the response of several classes of SH2
domains to TKI treatment. We chose Grb2 and Shc family
members (Grb2, Grb2(SH23), Grap, Grap2, ShcA, ShcA(ptb))
because of the known importance of Ras activation to
tumorigenesis, and our earlier results linking Ras activation to
erlotinib sensitivity (Fig. 4); and PI3Ks (p85A, P85B, P55G),
because of the strong association between PI3K/Akt activity and
cancer [40]. We also analyzed binding of Crk proteins (Crk and
CRKL) and Nck proteins (Nck1 and Nck2), based on the
involvement of these adaptors in RTK-dependent actin cyto-
skeletal rearrangements [41,42] and our unpublished observa-
tions that these SH2 domains bind to distinct targets compared to
most RTK effectors. We found that binding of the SH2 domains
of RAS activators, Crks, and PI3Ks decreased with TKI
treatment, with the exception of H292 cells (Fig. 7B). Ncks were
unique in that SH2 binding consistently increased upon TKI
t r e a t m e n t( F i g .7 B ,S u p p l .F i g .S 4 B ). This is consistent with other
work showing that Nck binding sites diminish upon RTK
stimulation, in concert with loss of focal adhesions and stress
fibers ([42] and L. Jia, KM, and BJM, unpublished observation).
On average, the degree of change in binding of RAS activators
approximates the erlotinib sensitivity of the cells; for HCC827,
H358, and H441 cells the average log2 fold change is 23.1, 21.6,
and 20.8, respectively. For dasatinib, inhibition of the PI3K
pathway may also be important, as PI3K SH2 binding is reduced
significantly in H358, whereas in the resistant H441 line binding
is virtually unchanged. H292 cells have an anomalous pTyr
response to TKI that may reflect very low overall tyrosine
phosphorylation levels and lack of either EGFR or KRAS
mutation in this line.
When quantitative changes in SH2 binding upon TKI
treatment were used as the basis for unsupervised hierarchical
clustering, several general principles become apparent (Fig. 7C,
Suppl. Fig. S5). For HCC827, H358, and H441, the same cell
lines treated with different inhibitors were more similar in their
responses than different cell lines treated with the same inhibitor.
Thus for each of these three cell lines, the critical molecular targets
for both erlotinib and dasatinib are likely to overlap. However, the
dissimilarity in the responses to TKI when different cell lines are
compared indicates that these critical targets are not identical in
the three lines. The fact that the response of a particular cell line to
different TKI is more similar than the response of different cell
lines to the same TKI is interesting and rather unexpected,
suggesting that TKI response is highly dependent on the cell-
specific signaling milieu. This idea is reinforced by the anomalous
response of H292, which suggests these cells are driven by very
different molecular abnormalities, and that their TKI-induced cell
cycle arrest is mechanistically distinct from that seen in the other
lines. Therefore SH2 profiling provides novel insight into the
mechanisms whereby TKI suppress tumor cell growth, though
much more work is needed to correlate particular phosphorylation
changes with biological responses to TKI.
Discussion
Our results strongly suggest that SH2 profiling is a useful
molecular diagnostic approach for analyzing tyrosine kinase
signaling in tumor cells. Not only can the overall SH2 profiling
patterns serve as the basis for classification of tumors with potential
prognostic and/or predictive value, but this approach can also
identify molecular probes and phosphorylated proteins that may
individually or in combination serve as clinically useful biomark-
ers. This strategy combines the advantages of global analysis,
which does not depend on preconceived notions of the key
molecular drivers involved, with a tight focus on tyrosine
phosphorylation, which is known to play a central role in many
aspects of tumor biology.
Our studies were initially driven by the hypothesis that in lung
cancer cell lines, tyrosine phosphorylation patterns would be
related to the state of EGFR signaling, and in particular to EGFR
mutation status. Consistent with this idea, we found higher binding
of several SH2 probes, including Grb2 and ShcA, in EGFR
mutant cells. However mutant EGFR does not drive the entire
tyrosine phosphorylation pattern in lung cancer, as cells with
mutant EGFR can form distinct clusters. This is perhaps not
surprising given the abundance of tyrosine kinases implicated in
lung cancer biology [4]. Our results are also consistent with the
finding that distinct mutant alleles of EGFR can lead to
measurable differences in tyrosine phosphorylated peptides [25].
SH2 profiling therefore reveals heterogeneity of downstream
signaling outputs despite common genomic properties (EGFR
mutation), and could therefore provide additional predictive or
prognostic information in tumor classification.
It is interesting to note that classification based on SH2 profiles
correlated quite closely with two other molecular markers, MET
activation and K-RAS activation. In the case of MET, both rosette
and far-Western SH2 profiling clearly distinguished a cluster of
cells with high levels of activating MET phosphorylation. This
strongly suggests that in lung cancer, global patterns of tyrosine
phosphorylation are at least as dependent on MET activation as
they are on EGFR mutation. This important and rather
unexpected insight is a clear indication of the value of unbiased,
global approaches.
The correlation we observed between SH2 binding pattern and
activating RAS mutation (Fig. 2B) is also surprising, given that
RAS is expected to act downstream of tyrosine kinases (thus
Figure 6. SH2 domains correlated with MET activation. (A) SH2 domains correlated with MET phosphorylation (p,0.01, q,0.1). Bar plot of
SH2 signal for high and low MET phosphorylation. Mean and standard errors are shown. For this analysis ‘‘Low’’ includes both intermediate and low/
negative categories (Fig. 5). (B) Far-Western domain-specific bands correlated with MET phosphorylation. Colored boxes indicate statistical
significance in Mann-Whitney test for differences (q,0.1). (C) H1648 cells were exposed to control (DMSO), 1000 nM erlotinib (E), 1000 nM
PHA665752 (P), or combination (E+P) for 3 h and analyzed by immunoblotting. Lysates from untreated H820 cells served as control for p-MET. Anti-b-
actin was used to confirm equal loading. (D) Cell viability for H1648 cells exposed to 60 nM erlotinib (E), 300 nM PHA665752 (P), or combination
(E+P).
doi:10.1371/journal.pone.0013470.g006
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PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13470Figure 7. SH2 profiling of cells treated with erlotinib or dasatinib. Change in SH2 binding in presence of EGFR TKI (erlotinib) or SRC TKI (dasatinib)
for four lung cancer cell lines (H292, H358, H441 and HCC827). Cells were treated for 1 h with inhibitors prior to analysis. (A)T h el o g 2 fold change in SH2
binding upon erlotinib and dasatinib treatment (relative to untreated) as determined by rosette assay is shown for all probes, ranked in order of fold change
in response toerlotinib. Each cell line is represented in a separate panel. For each SH2 domain probe, values for changes upon erlotinib treatment are shown
asred bars, for dasatinibas blue bars. Colored arrows indicate positionof SH2domainsfor RASactivators (blue), PI3Ks(green), Crk family (red), andN c kf a m i l y
(purple). (B) Bar graph of mean log2 fold change for indicated SH2 domain groups and cell lines treated with erlotinib (E) or dasatinib (D). (C)D e n d r o g r a m s
obtained from hierarchical clustering of log2 fold changes (TKI-treated vs. untreated).Results for rosette assay are shown on top and far-Western blotting
below. See Suppl. Fig. S5A for heatmaps.
doi:10.1371/journal.pone.0013470.g007
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pTyr-based signals). This result implies that SH2 profiling provides
useful information even for tumors not driven by tyrosine kinase
activation. Notably, of the three K-RAS mutant cells not included
in the major cluster of K-RAS mutants (Fig. 2B), H441 and H358
have recently been reported to have a more epithelial phenotype
[43], while A549 was shown to have a mixed epithelial-
mesenchymal phenotype [44]. Thus, SH2 profiles may also reflect
the epithelial phenotype in the context of K-RAS mutation. The
fact that most K-RAS mutant cells cluster together also implies a
common pattern of tyrosine phosphorylation in cells where RAS
activity is decoupled from RTK activation. Such a pattern could
be generated by feedback loops that normally function to
downregulate pTyr signaling following RAS activation. We note
that while overall SH2 binding is decreased in the mutant RAS
cluster compared to other cell lines (see cluster 3, Fig. 2B), in far-
Western blots the binding of the ubiquitin ligases CblA and CblB
to high-molecular weight phosphoproteins is increased in these
cells, consistent with Cbl-dependent downregulation of RTKs.
Guha and colleagues also observed decreased tyrosine phosphor-
ylation of several proteins in human bronchial epithelial cells
expressing mutant K-RAS [25].
The results presented here suggest that SH2 domain binding
sites could be used as biomarkers of EGFR TKI sensitivity. We
found 13 probes whose binding correlated with erlotinib
sensitivity. A number of these, including Grb2 and ShcA, are
from proteins predicted to promote downstream activation of the
RAS/MAPK pathway when bound to activated RTKs. Similar
correlations were seen for SH2 domains of PI3K and PLCc, two
other key pathways downstream of EGFR signaling. It is
particularly striking that binding sites for known RAS pathway
activators are associated both with activating EGFR mutations
and with erlotinib sensitivity. RAS activation has long been
associated with proliferative signals, and RAS itself is activated by
mutation in a large number of human cancers. By examining pTyr
signaling in an unbiased fashion on a global scale, our results
confirm the central importance of RAS signaling in lung cancer,
and suggest that particularly strong activation of RAS may be a
hallmark of cancers that are driven by EGF receptor mutation and
are sensitive to EGFR inhibitors (i.e. are ‘‘addicted’’ to EGFR
signaling). It will be important to determine how SH2 profiling
could add additional information beyond known predictors of
EGFR TKI response such as EGFR mutation status, gene
amplification, gene expression profiles, and autocrine signaling
[13,14,15,17,18,19,45]. In particular, developing predictors based
on multiple SH2 domain probes is likely to improve the
discriminating power of SH2 profiling, and is therefore a high
priority for future studies.
Importantly, SH2 domain profiling interrogates the entire
spectrum of tyrosine phosphorylation sites, thereby detecting
signaling driven by diverse tyrosine kinases in their native cellular
environment. Using this approach we were able to identify a
pattern of SH2 binding characteristic of cells driven both by
EGFR and MET that could require dual EGFR and MET
inhibition to block downstream signaling. In one example, we
showed that in H1648 cells, which cluster together with other cell
lines in which EGFR and MET signaling is co-activated,
downstream signaling and cell growth were synergistically
inhibited by erlotinib and PHA665752, a MET-specific TKI.
Thus, information provided by SH2 profiling may be useful for
guiding therapeutic decisions. Future studies will explore the
potential correlation of SH2 binding patterns with activation of
other RTKs implicated in lung cancer, such as IGFR, FGFR,
PDGFR, ALK, and EPH receptors.
SH2 profiling is highly complementary to other current
methods for analyzing global tyrosine phosphorylation patterns,
such as phosphospecific antibodies and MS [46,47]. Phosphospe-
cific antibodies (raised against specific tyrosine phosphorylated
sites) can be sensitive and specific, but have the disadvantage that
they require knowledge of the relevant phosphorylated sites, and
they are available for only a small fraction of known sites. Mass
spectrometry (with or without initial enrichment by pull-down or
immunoprecipitation using anti-pTyr antibodies) can be used to
identify specific phosphorylated sites in a sample [4,25], but has
the disadvantages that coverage and sensitivity are modest,
relatively large amounts of sample are required, and absolute
quantification of individual sites is difficult. By contrast, SH2
profiling is comprehensive, highly sensitive, and quantitative, but
has the disadvantage that the individual phosphoproteins respon-
sible for SH2 binding are not identified. Ultimately, the
combination of SH2 profiling with MS analysis of selected
samples should allow the development of specific and sensitive
molecular tests to discriminate tumor subtypes based on tyrosine
phosphorylation pattern. We note that three cell lines used in this
study (HCC827, H441, and H358) were also analyzed by Rikova
et al. using MS [4]. Their clustering results (based on MS) and ours
based on SH2 profiling agree that HCC827 and H441 are very
closely related by pTyr pattern; in the case of H358, clustering
based on MS and rosette suggest these cells are rather distantly
related to the other two lines, while clustering based on FW
blotting suggests a closer relationship.
Going forward, it will be important to demonstrate that primary
human lung cancer samples exhibit SH2 binding patterns similar
to those seen in lung cancer cell lines. Using the current rosette
assay, it is possible to profile the level of binding for virtually all
SH2 domains using less than 100 mg total protein. We and
colleagues have also developed a high-throughput multiplexed
SH2 profiling platform based on tagging of SH2 domains with
specific oligonucleotides [27]. Because a PCR amplification step
makes this assay extremely sensitive, it may provide the basis in the
future for standardized clinical SH2 profiling assays for molecular
diagnostics.
SH2 domain profiling of TKI-treated cells also provides a novel,
global approach to understand kinase inhibitor activity in vivo.
Comprehensive analysis of changes in tyrosine phosphorylation in
response to TKI is likely to highlight key targets of inhibitor action
and uncover differences in cellular responses to inhibitors.
Surprisingly, we found some tumor cells (H358 and H441) had
very similar pTyr responses to two distinct TKI (erlotinib and
dasatinib), despite the different spectrum of kinases inhibited by
these agents. In principle SH2 profiling could be used to compare
multiple TKI responses and to group kinase inhibitors according
to mechanism of action. This is analogous to the efforts of the
Connectivity Project, which uses gene expression as a way to
group chemical compounds with similar mechanism of action
[48]. Given the promiscuity of some inhibitors such as dasatinib,
this may be one way to assess the overall impact of inhibiting
multiple kinases in concert [38,39].
In conclusion, our results demonstrate that SH2 profiling can
recognize distinct patterns of EGFR signaling in lung cancer cells,
and more broadly provides a straightforward and comprehensive
approach to profile the global state of tyrosine phosphorylation
signaling in tumors. These results could inform therapeutic
decisions regarding TKI in lung cancer, and can provide a novel
basis for tumor classification complementary to existing methods.
This approach also provides new insights into the basic wiring of
tyrosine kinase signaling networks in tumor cells, and how those
networks are affected by TKI treatment.
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Cell Lines and Reagents
Human lung cancer cell lines H292, H358, H441, A549, H460,
H1703 and H1299 were obtained from ATCC (Manassas, VA).
HCC827 cells were provided by Dr. Jon Kurie (MD Anderson
Cancer Center), H1648, H2122, H226 and H157 cells were
provided by Dr. John Minna (UT Southwestern Medical Center),
H322 were provided by Dr. Paul Bunn (University of Colorado),
H23 cells were provided by Dr. Gerold Bepler (Moffitt Cancer
Center), and UK29 cells were provided by Dr. Penni Black
(University of Kentucky). All cell lines were maintained in RPMI-
1640 medium supplemented with 10% newborn calf serum (NCS)
from Sigma (St. Louis, MO). Erlotinib was provided by OSI
Pharmaceuticals (Melville, NY), dasatinib by Bristol Myers
Oncology (Princeton, NJ), and PHA665752 by Pfizer (San Diego,
CA) [36]. Stock solutions in 100% DMSO were diluted directly in
the media to indicated concentrations.
SH2 Profiling
SH2/PTB domain binding assays were performed as described
[28,49]. Briefly, lung cancer cell lines were lysed in KLB buffer
(150 mM NaCl, 25 mM Tris-HCl pH 7.4, 5 mM ethylene
diamine tetraacetic acid (EDTA), 1 mM phenyl methyl sulfonyl
fluoride (PMSF), 1% Triton X-100, 10% glycerol, 0.1% sodium
pyrophosphate, 10 mM b-glycerophosphate, 10 mM NaF,
5 mg/ml of Aprotinin (Sigma A6279, St. Louis MO), 50 mM
pervanadate). Precipitated proteins were resuspended in spotting
solution (180 mM Tris–HCl, pH 6.8, 30% glycerol, 6% sodium
dodecyl sulfate (SDS), 15% b-mercaptoethanol, and 0.03%
bromophenol blue) and briefly boiled. 0.1 ml lysate (400 ng total
protein) was spotted in arrays on nitrocellulose membranes and
incubated with purified GST-SH2 or -PTB domains (,100 nM)
for 2 h. Probe binding was detected by enhanced chemilumines-
cence (ECL) (PerkinElmer, Waltham MA) using HRP-labeled
anti-GST antibody (Sigma A7340) or GSH-glutathione conjugate
(Sigma G6400) and digitally captured (Kodak Image Station). The
binding assay was performed four times, including at least two
separate experiments, and average signal intensity for each spot
was quantified by densitometry (ImageJ v1.40).
Far-Western analysis for lung cancer cell lysates was performed
as described [50,51]. Briefly, proteins were separated by SDS-
PAGE using NuPAGE precast gels (Invitrogen, Grand City NY)
and transferred to nitrocellulose membranes. Replica membranes
were incubated with GST-SH2 domains for 2 h, and bands were
detected by ECL and digitally captured. Blots were stripped and
reprobed several times with additional SH2 domains and anti-
pTyr antibody (PY100, Cell Signaling, Beverly MA). To quantify
bands on multiple blots derived from different gels, SH2 blot
images were aligned in reference to corresponding anti-pTyr blots
using Photoshop (Adobe). The aligned blot images from two
independent experiments were quantified using a custom-made
plug-in written for ImageJ densitometry (H. Zhang, J. Maddox,
and D.G. Shin, University of Connecticut).
Protein Expression Analysis
Cells were washed with ice-cold PBS and extracted with chilled
lysis buffer (10 mM Tris, pH 8.0, 60 mM KCl, 1 mM EDTA,
1 mM DTT, 0.5% NP-40, 10 mM Na3VO4, 50 mM NaF, 1 mM
PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin).
Total cellular proteins were separated on SDS-PAGE, transferred
to nitrocellulose membranes, and probed with rabbit polyclonal
antibodies specific for pTyr 1344/45 MET, pThr202/Tyr204-
p44/42 ERK, and pSer473 AKT (Cell Signaling) and b-actin
(Sigma). Detection was by horseradish-peroxidase conjugated
secondary antibodies and ECL (Amersham, Piscataway, NJ).
Drug Sensitivity Assays
Cell viability assays (MTT) were performed using the Cell
Proliferation Kit (Roche, Indianapolis, IN) following the manu-
facturer’s recommendations. Cells were plated at 2–5610
3 cells
per well in 96-well plates, incubated overnight, exposed to a serial
dilution of dasatinb or erlotinib in complete media with 5%
newborn calf serum, and viability assessed after 5 d. The IC50 was
calculated by non-linear regression analyses using MATLAB
scripts that pair data points with sigmoidal curves that predict a
signal response based on a four-parameter fit. Data presented
represent three separate experiments with 8 data points separating
each dose per condition. Data are expressed as mean 6 SD.
EGFR and K-RAS Genotyping
Genomic DNA extraction from each NSCLC cultured cell lines
was performed using DNeasy Kit (Qiagen, Du ¨sseldorf). Sequencing
of exon 19, 20, and 21 of EGFR was performed as previously
described [15]. For K-RAS, the primers were K-RAS exon 1
(forward), 59 TTAACCTTATGTGTGACATGTTCTAA-39 and
(reverse) 59-AGAATGGTCCTGCACCAGTAA-39,w h i c hg e n e r -
ates a fragment of 225 bp, and K-RAS exon 2 (forward), 59-
TCAAGTCCTTTGCCCATTTT-39and (reverse) 59-TGCATGG-
CATTAGCAAAGAC-39, which generates a fragment of 374 bp.
Network Analysis
SH2 domain binding data were input into PPI Spider (http://
mips.helmholtz-muenchen.de/proj/ppispider/). Analyses were
run with 100 random networks and only proteins that directly
connect to each other through no more than one edge were
allowed for visualization. Networks were subsequently input into
Cytoscape for visualization.
Clustering Analysis
For rosette data, hierarchical clustering was performed on the
70 probes (after median centering) using full linkage and
uncentered correlation using Cluster 3.0 and Java Treeview. For
far-Western data, 720 domain-specific bands (20 bands635 SH2
domains) were filtered to retain those with a standard deviation
.5, and at least 11 of 22 cell lines having intensity above 5.0 for a
specific domain-specific band. Hierarchical clustering was per-
formed on the remaining 188 bands using full linkage and
uncentered correlation using Cluster 3.0 and visualized using Java
Treeview. No normalization was used in clustering, but for
visualization purposes, the intensities were median-centered so
that green represents values below the median probe value and red
above. Further details on rosette and far-western data analysis are
provided in the Suppl. Methods S1 and Suppl. Figures S6 and S7.
Statistical Analysis
Details are described in Suppl. Methods S1. Briefly, hierarchical
clustering was performed using Cluster 3.0 and Java Treeview. To
identify probability of a clustering pattern occurring by chance,
permutation tests were performed. Domains were identified as
statistically significant with respect to dichotomous characteristics
using a Mann-Whitney test applied to each domain. To correct for
multiple testing problems, false discovery rates (q values) were
calculated using the Q Value package in Bioconductor [52] and a
10% FDR (q#0.1) was considered significant. Bar graphs showing
differences between groups were displayed using mean and
standard errors. Pearson’s correlation coefficient was computed
SH2 Profiling of Lung Cancer
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changes with treatment, differences in signal were quantified as the
log2 fold change (log2 (treated/untreated)) and hierarchical
clustering was performed using these values.
Supporting Information
Supplemental Methods S1 Supplemental methods and
references.
Found at: doi:10.1371/journal.pone.0013470.s001 (0.05 MB
DOC)
Table S1 Characteristics of cell lines used in this study. Adeno
= adenocarcinoma; Squamous = squamous cell carcinoma; BAC
= bronchiolioalveolar carcinoma; Large = large cell carcinoma;
NOS = not otherwise specified; WT = wildtype.
Found at: doi:10.1371/journal.pone.0013470.s002 (0.06 MB
DOC)
Table S2 Processed SH2 binding data. Sheet 1: raw rosette data
used for the analysis. The matrix consists of 70 (SH2 domain
probes)622 (lung cancer cell lines). 26 domains with lower signal
were removed based on statistical analysis (Figure S2; see also
supplementary methods, below). Sheet 2: far-Western data used
for the analysis. The matrix consists of 720 (SH2 domain
probe_bin number) 622 (lung cancer cell lines).
Found at: doi:10.1371/journal.pone.0013470.s003 (0.36 MB
XLS)
Table S3 List of probes used in this study. 96 far-Western probes
consist of 94 GST-SH2 domains, a GST-PTB domain (ShcA), and
GST alone (negative control). Probe name, protein name, Entrez
GeneID, source organism, SH2 insert amino acid region, and
structure of construct are shown.
Found at: doi:10.1371/journal.pone.0013470.s004 (0.02 MB
XLS)
Figure S1 SH2 rosette assays. The SH2 rosette assay (high
throughput dot blotting) was performed as described [1,2]. Lung
cancer and control cell lysates were spotted in duplicate on
nitrocellulose membrane as indicated (top) in register with wells of
a 96-well chamber plate. Each well was separately incubated with
GST-SH2/PTB domain, GST control, anti-phosphotyrosine
antibody, or anti-actin antibody (probe list is on the right).
Control = negative control (phosphatase-treated lysate); p-control
= positive control (mixed lysates from pervanadate-treated cell
lines); see [2] for details. Two independent experiments were
performed in duplicate, providing four quantifiable data points for
each probe/sample pair. Array images were background-subtract-
ed and the integrated density of each spot was measured using
ImageJ densitometry (v1.40).
Found at: doi:10.1371/journal.pone.0013470.s005 (5.97 MB TIF)
Figure S2 Correlation of Csk SH2 binding and EGFR mutation
status. Top: Signal intensity from far-Western analysis using CSK
SH2 probe was quantified in multiple blots. Black bars represent
average of two independent blots (Expt. 1; these data are provided
in Suppl. Table S2 and were used for clustering analysis). White
bars represent data from an independent blot performed at
another time with a subset of cell lines. EGFR mutation status of
cell lines (mut = mutant, wt = wild-type) is indicated below.
Bottom: Average CSK signal intensity for mutant vs. wt cell lines.
Differences are statistically significant by unpaired T test as
indicated by P values.
Found at: doi:10.1371/journal.pone.0013470.s006 (1.64 MB TIF)
Figure S3 MET and EGFR family activation. (A) Left: Lysates
from lung cancer cell lines were separated by SDS-PAGE,
transferred to membranes, and blotted with phosphospecific
anti-MET antibody (recognizing pY1334/1335). Signal was
detected by chemiluminescence and the pMET band (arrow)
was quantified using ImageJ densitometry. Representative blot
(upper) and quantified result from multiple experiments (lower) are
shown. Right: Similarly, protein bands of approximately 194 kDa
on anti-pTyr blots (at molecular weight of EGFR family members,
arrow) were quantified. Values are given as percent of maximum
signal. (B) Cell lines indicated were treated with vehicle (DMSO),
or with erlotinib (E1000) or PHA665752 (PHA1000) at 1 mM for
24 h to inhibit EGFR or MET, respectively. Immunoblots were
probed with different antibodies or p85a SH2 domain as indicated
on right. Tyrosine phosphorylation and binding of p85A SH2
domain to proteins in the MW194 bin was strongly inhibited by
erlotinib in erlotinib-sensitive cells (red arrows), while tyrosine
phosphorylation and binding of p85A SH2 domain to proteins in
the MW148 bin was strongly inhibited by PHA665752 (blue
arrows). (C) HCC827 cell lysates were immunoprecipitated twice
with antibody to MET (top) or EGFR (bottom). Lysate before
immunoprecipitation (PreIP), first immunoprecipitate (P1), second
immunoprecipitate (P2), and cleared lysate after immunoprecip-
itation (postIP) were immunoblotted with anti-MET or anti-EGFR
antibodies or probed with p85a SH2 domain as indicated.
Found at: doi:10.1371/journal.pone.0013470.s007 (9.02 MB TIF)
Figure S4 Changes in SH2 profiles following TKI treatment. (A)
Median fold change (FC) and the median absolute deviation
(MAD) for all SH2 domains whose binding significantly changed
(p,=0.125) by rosette assay after treatment with EGFR TKI. (B)
Heat maps of far-Western binding data for each cell line treated
with each tyrosine kinase inhibitor. Green indicates reduction in
SH2 domain binding while red indicates increase in SH2 domain
binding after TKI treatment. Each SH2 domain used for profiling
is listed in columns and molecular weight bin is listed in rows.
Found at: doi:10.1371/journal.pone.0013470.s008 (9.80 MB TIF)
Figure S5 Correlation of changes in SH2 profiles following TKI
treatment. (A) Heat map of log2 fold changes (TKI-treated vs.
untreated) from hierarchical clustering. Results for rosette are
shown on left and far-Western blotting on right. (B) Pearson’s
correlation matrix shows overall similarity in fold changes between
different cell lines and different treatments (compared to untreated
cells; D, dasatinib-treated; E, erlotinib treated) for both the rosette
and far-Western assays.
Found at: doi:10.1371/journal.pone.0013470.s009 (7.04 MB TIF)
Figure S6 Preprocessing of the rosette data (referred to in
Supplemental Methods). (A) Examining potential batch effects in
the rosette assay. (B) Coefficient of Variation (CV) expressed as
mean of the CV calculated for each cell line. (C) Histogram of
signal level for the Abl domain. The histogram suggests intensities
are not normally distributed. (D) Histogram of p values from the
Shapiro test for normality. Most probes do not appear to be
normally distributed. (E) Histograms of normally distributed SH2
domains. Histogram of Vav3 (left) and Rin1 (right) signal, with
negative (green) and positive (red) controls indicated. (F)
Histogram of differences in positive and negative controls across
probes. 13 domains have differences ,0 (white bar). (G)
Histogram of domains with small differences between the positive
and negative controls. Many are near 0. (H) Multidimensional
Scaling (MDS) scatter plots of samples using (left) all domains,
(right) filtered domains. Positive control (red) and negative control
(green) are indicated. Similarity of samples is represented as
pairwise distances. There does not appear to be any significant
change in the relationship between samples as a result of filtering
"noisy" probes.
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Figure S7 Processing of far-Western blotting data (referred to in
Supplemental Methods). (A) Alignment and quantification of
multiple far-Western blotting results. Blot images from same gel
were aligned using a frame marker of reference shots taken under
normal white light during image scanning (Frame alignment). The
aligned images were linked (Aligned lock) and further aligned with
images from different gels using corresponding anti-phosphotyr-
osine Western blots. (B) Far-Western images were captured and
partitioned into 20 grid elements (bins) per lane. Rows were
numbered from the largest molecular weight (256–291 kDa) to
smallest (,22 kDa). (C) Mapping of far-Western grid row and
molecular weight. (D) Correlation between far-Western molecular
weight bins across cell lines, between replicates. (E) Boxplot of far-
Western signal for bins with correlation coefficients less than 0.5
between replicates. In most cases poor correlation is due to low
signal.
Found at: doi:10.1371/journal.pone.0013470.s011 (9.67 MB TIF)
Movie S1 SH2 far-Western blot results. Images of far-Western
blotting results are compiled as a movie. SH2 domain binding
experiments were performed on lysates of untreated (first half of
the movie) and TKI-treated (second half of the movie) lung cancer
cell lines. After correction for blot-to-blot variation (as shown in
Figure S3), replica blots from two separate experiments were used
for quantification of 20 bins per gel lane. Red grid lines indicate
the location of bins used for quantification; pink line on top
indicates EGFR-mutated cells. Approximate molecular size (in
kDa) indicated in blue for each bin.
Found at: doi:10.1371/journal.pone.0013470.s012 (14.14 MB
MOV)
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